Bristol-Myers Squibb And Pfizer Provide Update On Apixaban Clinical Development Program

�Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The companies announced that new Phase II information in piercing coronary syndrome patients (ACS) will be presented at the forthcoming meeting of the European Society of Cardiology (ESC). In addition, Bristol-Myers Squibb and Pfizer reported that an early evaluation of results from a Phase III subject field of apixaban for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement indicates that the primary terminus of this study was not met.


The Phase III VTE prevention written report known as ADVANCE-1 compared apixaban, a novel, oral Factor Xa inhibitor granted at a dose of 2.5 mg, twice daily, to the FDA-approved dose of enoxaparin, 30 mg tending twice everyday. The primary efficacy result was a composite of symptomatic or asymptomatic deep vein thrombosis, pulmonary embolism, and destruction by whatsoever cause. The rate of the primary efficacy termination on apixaban was numerically similar to that ascertained with enoxaparin (9.0% vs. 8.9%, p=.064), simply did non meet the pre-specified statistical criteria for non-inferiority compared to enoxaparin. The factual enoxaparin VTE rate of 8.9 percent was lower than the expected VTE rate of 16 percent seen in late similar clinical trials, resulting in an inability to demonstrate non-inferiority.


In ADVANCE-1, there were no unexpected findings in adverse events for apixaban compared to enoxaparin. The major hemorrhage event pace for apixaban was numerically lower, but was not significantly lour, than enoxaparin (0.7% vs. 1.4%, p=.053). The composite rate of clinically relevant non-major bleeding and major haemorrhage was significantly less in patients wHO received apixaban than those who received enoxaparin (2.9% vs. 4.3%, p =.034).


Full results of the ADVANCE-1 trial have been submitted to the American Society of Hematology Meeting (ASH) for presentation in December.


ADVANCE-1 results confirm the characteristics of apixaban as reported antecedently in phase angle II studies. The companies are considering further studies with different protocols in preventing VTE in knee surgery and will non submit the U.S. filing for VTE prevention in the 2nd half of 2009, as previously communicated. The results of ADVANCE -1 do not demand any changes in protocols of whatever other on-going apixaban studies. Programs directed towards prevention of VTE including EMEA registrational studies, treatment of VTE, and in the prevention of stroke in atrial fibrillation continue as planned.


"Bristol-Myers Squibb and Pfizer stay enthusiastic and committed to the clinical development programme for apixaban," said Jack Lawrence, vice president, Research and Development, Bristol-Myers Squibb. "Bristol-Myers Squibb and Pfizer anticipate that the results of APPRAISE-1 being presented at ESC will provide important penetration into the potential use of apixaban for the secondary prevention of cardiovascular events in patients with acute coronary thrombosis syndrome, which affects an estimated 2.7 gazillion people around the mankind every year."

About the Apixaban Clinical Program


Apixaban, an oral, factor Xa inhibitor in a new class of agents that have shown therapeutic potential to foreclose and treat blood clots, is presently being explored in the EXPANSE clinical trial programme which includes eight Phase III clinical studies involving approximately 45,000 patients worldwide. The ADVANCE-2 and 3 trials are investigating the safety and efficacy of apixaban 2.5 mg double daily compared to enoxaparin 40 mg once casual in patients undergoing major orthopedic surgery. The ADOPT study is investigating apixaban for one month compared to standard of attention (enoxaparin 40 mg one time daily for at least 6 years followed by placebo) for the prevention of VTE in hospitalized patients wHO are medically ill and at risk of VTE.


Apixaban is also in Phase III trials studying the bar of cVA and other thromboembolic events in patients with atrial fibrillation (AF). The AF program consists of two trials. The ARISTOTLE trial is investigating apixaban compared to coumadin in or so 15,000 patients with atrial fibrillation. The AVERROES trial is investigating apixaban compared to aspirin in approximately 5,600 patients with atrial fibrillation world Health Organization are ineligible for vitamin K antagonists (VKA) treatment or haven't tolerated previous VKA discourse.


The VTE treatment program consists of two trials. The AMPLIFY trial is a 6-month trial investigating apixaban compared to enoxaparin plus coumadin in roughly 4,800 patients with acute DVT or PE. The AMPLIFY-EXT trial is a 12-month trial investigating apixaban compared to placebo for extended treatment to prevent perennial VTE in approximately 2,400 patients who let completed 6 to 12 months of treatment for DVT or PE.

About Bristol-Myers Squibb


Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human lifetime. For more information confab http://www.bms.com.

About Pfizer


Founded in 1849, Pfizer is the world's largest research-based pharmaceutic company. Pfizer is taking new approaches to advancing better health as it discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both hoi polloi and animals. For more information natter http://www.pfizer.com.

Bristol-Myers Squibb Forward-Looking Statement


This urge on release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialisation of products. Such innovative statements ar based on current expectations and involve inherent risks and uncertainties, including factors that could delay, deviate or change any of them, and could cause actual outcomes and results to disagree materially from current expectations. No advanced statement bum be guaranteed. Among other risks, there can be no warrant that the clinical trials described in this release will support a regulative filing or that the product will receive regulative approval. There can be no assurance that if approved, the product described in this release testament be commercially successful. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's line, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year concluded December 31, 2007, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update whatever forward-looking statement, whether as a upshot of unexampled information, next events, or otherwise.

Pfizer Forward-Looking Statement


The information contained in this release is as of August 26, 2008. Pfizer assumes no obligation to update forward-looking statements contained in this tone ending as the result of new info or succeeding events or developments.


This release contains forward-looking info about a product prospect, apixaban, including its potential difference benefits that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory government regarding whether and when to okay any drug applications that may be filed for such ware candidate as well as their decisions regarding labeling and other matters that could affect its accessibility or commercial potential; and competitive developments.


A further description of risks and uncertainties can buoy be institute in Pfizer's Annual Report on Form 10-K for the fiscal year concluded December 31, 2007 and in its reports on Form 10-Q and Form 8-K.

Pfizer


View drug information on Warfarin Sodium tablets.



More info

• High levels of toxic metals found in herbal medicines sold online
• Why Young Men Don’t Know How to Act
• Cats bigger threat to fish than people
• Monkeys too experience joy of giving
• Alzheimer’s vs. Dementia? Subtle Difference

Nas Calls On Rap's Veterans To 'get Real'

NAS insists its his rap peers' duty to "get real" and "make risks" as they suit hip-hop veterans.

The rap star, wHO recently sparked controversy by initially vocation his new album Nigger, insists high-living stars should write rhymes about veridical life instead of tracks about the jet-set and good living.

He says, "When you first set out into the music concern, you're delirious to be there, you want to make records that everybody's loving.

"But, after you've got long time in the game, you wanna give people the real side of you, show people some persona.

"Life is good; there's yachts, there's nice cars, there's picture show roles.

"We overcame... simply, in the middle of all that... you can't forget around the ones that didn't make it with us. Life is good, merely that inactive doesn't delete all the horror extinct here."

More information

• Download Crossover
• Spielberg’s Reliance deal ‘moving along fine’
• Download Steve Lacy
• How N.W.A made a rap believer of one nervous critic
• Download Nana Mouskouri

Yoko Ono tops the charts

For the fourth time in five years, Yoko Ono has hit the top bit of the American Billboard dance chart.

Ono made telephone number one with a remaking of Give Peace A Chance, a song often regarded as the anthem of Ono�s late husband John Lennon.

Upon news of the track hitting number one, Ono said �I thank you with all my tenderness and broadcast you much love.�

It is Ono�s second number of the class, after topping the terpsichore chart earlier this year with the track No No No. Ono likewise had graph success in 2003 and 2004.

More info

• Ashit Desai
• Son-Dha
• DJ Excalibah
• Willie Morales
• Gordian Knot

Sophie B. Hawkins

   
Artist: Sophie B. Hawkins

   Genre(s): 
Other
   

---

Discography:


   
 Tongues and Tails

   Year: 1992   
Tracks: 11

---

 

I'm not getting married, says Johansson

Following much media speculation that she could be about to walk down the aisle, a representative for actress Scarlett Johansson has said the star and actor Ryan Reynolds aren't getting married.
A New York newspaper and websites had reported the 23-year-old was seen shopping for wedding dresses with her mother and sister in Los Angeles.
But Johansson's spokesperson told Usmagazine.com:  "A family member is getting married, not her. She is not engaged."

Vitamin C

   
Artist: Vitamin C

   Genre(s): 
Dance
   

---

Discography:


   
 More

   Year: 2001   
Tracks: 14

---

Most adolescent come out singers are actual teenagers world Health Organization apparently try to moult their bubblegum look-alike and shoot for credibleness erstwhile they receive older. Vitamin C is a foreign exclusion: The quondam Colleen Fitzpatrick was lead vocaliser of the punk-pop band Eve's Plum showtime, and and then made the switch to explicitly teen-oriented dance-pop when that band broke up, by which sentence she was well into her late 1920s. Fitzpatrick was born July 20, 1972, in Old Bridge, NJ; she was a terpsichorean in high school earlier decorous a singer in respective local bands. She likewise tried acting, landing a function in John Waters' Hairspray in 1988. In 1991, she and guitarist Michael Kotch met while attending New York University and formed Eve's Plum together; later around a year, they landed a deal with Sony and wound up releasing two albums, 1993's Envy and 1995's Cherry Alive. Fitzpatrick afterwards left wing for a solo career, likewise pickings on performing roles in The Naked Gun 2 1/2, Liar Liar, The Mambo Kings, Dracula 2000, and Get Over It.


In the interim, Fitzpatrick refashioned herself as a dance-pop singer and scored a treat with Elektra in 1998. Her debut record album, Vitamin C, was released in tardy summertime 1999 and it produced two decent-sized hits in "Smile" (which featured Jamaican dancehall toaster Lady Saw) and "Me, Myself and I." Vitamin C truly took off, though, with the impeccably timed handout of the third single, "Graduation (Friends Forever)," the about blatantly teen-aimed song on the record. "Graduation (Friends Forever)" became a huge rack up in the give of 2000, hit the Top Ten and serving fight Vitamin C into platinum-sales territory. Fitzpatrick jumped on the marketing opportunities, licensing everything from her have doll to a shade of lipstick coordinated her signature orange River tomentum. Toward the end of 2000, the second Vitamin C album, More than, was issued, clean a more age-appropriate range and topic matter. Again, it spun off a mates of decent-sized hits in "The Itch" and "As Long as You're Loving Me," only it didn't make a breakaway boom on the order of "Gradation," and More than failed to crack the Top century.





Fauve is voted off You're A Star

Madonna: 'I Get Hotter With Age!'

Madonna reckons that she’s hotter now than at any other time in her life.
The singer insists she feels fitter, more toned and more attractive than ever as she approaches her 50th birthday in August.
"I like the way I look better now. My thighs aren't as chubby. I'm not kidding. I'm being perfectly honest," says the 4 Minutes star.
But Madonna - who stole the show when she hit the red carpet with Sharon Stone at Cannes this week - insists she has never thought of herself as a natural beauty: "I see myself as practical and handsome, and useful.
"I don't think of myself as a great beauty. But I think of myself as stylish."
Despite her professed contentment at her looks, the Material Girl reveals that she never looks at her old photos.
"I don't look at old pictures of myself. I don't look at pictures of myself from last week. Once I've approved of them, they're gone," she confesses
Madonna joins a host of fellow, more ‘mature’ beauties in our Stars Who Get Better With Age gallery – but is their secret good genes or a good plastic surgeon?
 

TV review: Brothers and Sisters

It's hard, while watching Brothers and Sisters, not to keep shouting from the sofa to Rob Lowe's character, who is about to marry into the series: Run! Get out while you can!

Thelonious Monk and Sonny Rollin

   
Artist: Thelonious Monk and Sonny Rollin

   Genre(s): 
Jazz
   

---

Discography:


   
 Thelonious Monk and Sonny Rollin

   Year: 1953   
Tracks: 5

---

 

Feist is winner of Shortlist Prize

Feist is winner of Shortlist Prize

Canadian singer-songwriter Feist has south Korean won the 2007 Shortlist Booty in the US for her album 'The Reminder'.
Hoarding reports that the judging panel for the prestigious laurels included C. P. Snow Patrol's Gary Lightbody and the Killers' Ronnie Vannucci.
Cat-o'-nine-tails Power's 'The Greatest' was the winner shoemaker's last year; previous winners include TV on the Tuner, Damien Elmer Leopold Rice, NERD and Sigur Ros.
Say the review of 'The Reminder' here.




Os Paralamas do Sucesso

Sparrows

   
Artist: Sparrows

   Genre(s): 
Soundtrack
   

---

Discography:


   
 World Of Worldcraft

   Year: 2003   
Tracks: 60

---

 





Lucinda Williams

Clooney: Kidman will be 'a perfect mother'

Clooney: Kidman will be 'a perfect mother'

George VI Clooney has congratulated Nicole Kidman on the word that she is pregnant by saying she will make 'a perfective tense mother.'
Clooney and Kidman receive been long-term friends, with the actress famously betting her friend $10,000 that he would still be a knight bachelor when he turned 40 in 2001.
Clooney told People magazine: "I'm thrilled for her. [She'll be] a perfective tense mother. She'll be great. She'll be a tall mother."
Kidman confirmed yesterday that she is expecting her starting time child with hubby, Keith Urban.
She already has adopted children with Tom Cruise, 15-year-old Queen Isabella and 12-year-old Connor.

Mudcrutch makes tracks

Mudcrutch makes tracks

Mudcrutch is either the quickest working band in john Rock ’n’ roll up or the slowest.
Turkey cock Petit larceny and a few of his Gainesville, Fla., buddies conjured their 14-track debut, “Mudcrutch,” in a mere 10 days. Impressive. Unless you count the fact that the set was founded in 1970 and is only now getting around to releasing its outset album.
Until latterly Mudcrutch was a footer in Petty’s history: the first band that he and future tense Heartbreakers guitar player Mike Joseph Campbell and keyboardist Benmont Tench played in. Long-forgotten were their Mudcrutch alums, singer/guitarist Uncle Tom Leadon and drummer Randall Marsh, as well as the band’s stomps through the swamps of FL between ’70 and ’75.



Only last summer, Petit larceny phoned Leadon and Ngaio Marsh and asked if they were interested in a reunion.
“I thought he was joking,” Leadon said from Calif., where Mudcrutch is finish a legal brief West Coast circuit to promote its album, released last week. “I thinking it wasn’t even Tom merely person pull my leg.”
But it was the real Tomcat. And he was real serious.
In August of finish class, Petit larceny invited Leadon and Reginald Marsh to impede at his place studio. To a lesser extent than 2 weeks later on the quintet had a record of land rock, bayou blues and one 9-minute psychedelic hippy close up (“Crystal River”).
“We determine up in a lot with simply the survive monitors and played and sang everything live together in one room,” said Leadon. “We got ‘Shady Grove’ in about trey takes. Everything sounded great and Tom turkey and Microphone said, ‘Well, that’s the criminal record.’
“I was like, ‘What? Are you certainly?’ But it worked and we did deuce or trey more songs that first day.”
“We started to have into a menstruation,” added Campbell. “Nearly of the stuff is fresh written and saucily played. Tom (Petty) went home every night and would come back the next clarence Shepard Day Jr. with a new song.”
The band worked out the arrangements to sometimes hours-old songs on the storey together. No headphones; no sequestering each musician in split sound booths. Petit larceny played bass and panax quinquefolius at the lapplander time, delivering un-self-conscious, unrefined vocals (best appreciated on the Heartbreakers-like “Bootleg Flyer”) a great deal paired with Leadon’s on the fly harmonies.
The sessions had an free energy, urgency and spontaneity Campbell said he hasn’t experienced since the betimes Heartbreakers albums.
“We wanted it to feel like it was back in the daytime,” he said. “It was form of a risk and we didn’t know if it would influence.”
But it did - and brilliantly. Especially for the brimming-with-emotion Leadon.
Friends since high school, Leadon and Petit larceny began their careers together. Just in mid-’70s, Leadon followed his older brother, Flying Burrito Brother and Eagles cofounder Bernie Leadon, to Calif. in pursuit of his country-rock muse. Over the years, as Petty larceny transitioned from bar ring crooner to icon, the deuce felled seam come out of touch.
“I didn’t need to hemipteron him too much,” said Leadon. “But I very missed him. We were as close, closer and then most brothers, and that’s division of what’s so nice about this. This unit thing has been truly special for me emotionally.”

Stars to boycott Golden Globes

Stars to boycott Golden Globes

Hollywood actors are to boycott this month's Golden Globe Awards to show documentation for striking writers.
Screen Actors Social club President Alan Rosenberg said in a argument in that location was "unanimous correspondence" among actors not to cross picket lines fructify up by the Writers Society of America world Health Organization are locked in a bitter difference of opinion with picture show and television system producers.
Rosenberg said the boycott would get over altogether nominees up for  acting awards in the event on 13 Jan.
The Golden Globes is regarded as the secondment most important awards show in Hollywood later on the Oscars.
The ban would also cover stars playing as presenters.
The decision means that nominated A-listers such as Julia Roberts, Tom Hanks and Saint George Clooney are entirely in all probability to steer clear of the Globes, greatly diminishing one of the highlights of Hollywood's awards season.
Hollywood screenwriters have been on strike since 5 Nov afterwards the WGA and the Alliance of Gesture Characterisation and Television  Producers failed to agree terms for a new contract.
Negotiations failed over the writers' demands for an increased part of win from Net and newly media gross revenue.
The two-month hit has forced the pause of numerous idiot box series as well as the deferment of cultivate on several Hollywood films.
The WGA confirmed this week that it would mount pickets or so the Golden Globes venue at the Beverly Hilton hotel.
It had already announced last calendar month that it would non leave club members to claim piece at both the Golden Globes and the Oscars.

Winehouse's husband voted top 'Anti-Icon'

Winehouse's husband voted top 'Anti-Icon'

Amy Winehouse's married man William Blake Fielder-Civil has been voted Britain's height Anti-Icon.
Readers of men's magazine Arena compiled a list of "witless" male celebrities wHO least deserve their shoes in the spot.
Fielder-Civil - currently on lag in Pentonville Prison house awaiting test - headed the Whirligig 10.
Indorsement on the lean was Banksy, the graffiti artist wHO counts Angelina Jolie and St. Jude Practice of law among his fans.
England and Chelsea footballer Frankfurter Lampard was third, accused of "weakness the country" with his lacklustre video display in the Euro 2008 qualifiers.
Falsetto-voiced isaac Bashevis Singer Mika was twenty-five percent, followed by daytime TV host Jeremy Kyle.
Peter Andre was sixth for forming "half of Britain's most over-exposed match" with glamour poser wife Jordan River, and ex-'Big Brother' housemate Ziggy was one-seventh. Pop principal Prince was eighth.
TV presenting couple Pismire and December were ninth and 'Top Gear's Richard Hammond was 10th.